Citations (23)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (3)
David P Nicolau. (2009) Management of complicated infections in the era of antimicrobial resistance: the role of tigecycline. Expert Opinion on Pharmacotherapy 10:7, pages 1213-1222.
Read now
Read now
Steven J. Edwards, Mike J. Clarke, Sarah Wordsworth & Nicky J. Welton. (2009) Carbapenems versus other beta-lactams in the treatment of hospitalised patients with infection: a mixed treatment comparison. Current Medical Research and Opinion 25:1, pages 251-261.
Read now
Read now
David P Nicolau. (2008) Carbapenems: a potent class of antibiotics. Expert Opinion on Pharmacotherapy 9:1, pages 23-37.
Read now
Read now
Articles from other publishers (20)
Meysam Seyedifar, Menhajuddin SabouriOmid SoodiHananeh Ghasemi. (2023) Budget impact analysis of temocillin insurance coverage for urinary tract infections caused by ESBL-producing pathogens in Iran. Medicine 102:35, pages e34436.
Crossref
Crossref
Susanna Esposito, Giacomo Biasucci, Andrea Pasini, Barbara Predieri, Gianluca Vergine, Antonella Crisafi, Cristina Malaventura, Luca Casadio, Marcello Sella, Luca Pierantoni, Claudia Gatti, Letizia Paglialonga, Chiara Sodini, Claudio La Scola, Luca Bernardi, Giovanni Autore, Giulia Dal Canto, Alberto Argentiero, Sante Cantatore, Martina Ceccoli, Alessandro De Fanti, Agnese Suppiej, Marcello Lanari, Nicola Principi, Andrea Pession & Lorenzo Iughetti. (2022) Antibiotic Resistance in Paediatric Febrile Urinary Tract Infections. Journal of Global Antimicrobial Resistance 29, pages 499-506.
Crossref
Crossref
Michelle Mahony, Brendan McMullan, Jeremy Brown & Sean E Kennedy. (2019) Multidrug-resistant organisms in urinary tract infections in children. Pediatric Nephrology 35:9, pages 1563-1573.
Crossref
Crossref
Katerina Tori, Giannoula S. Tansarli, Diane M. Parente, Markos Kalligeros, Panayiotis D. Ziakas & Eleftherios Mylonakis. (2020) The cost-effectiveness of empirical antibiotic treatments for high-risk febrile neutropenic patients. Medicine 99:20, pages e20022.
Crossref
Crossref
François Labaste, Julia Grossac, Fanny Vardon Bounes, Jean-Marie Conil, Stéphanie Ruiz, Thierry Seguin, Marion Grare, Olivier Fourcade, Vincent Minville & Bernard Georges. (2019) Risk factors for acquisition of carbapenem-resistance during treatment with carbapenem in the intensive care unit: a prospective study. European Journal of Clinical Microbiology & Infectious Diseases 38:11, pages 2077-2085.
Crossref
Crossref
Le Zou, Fanqi Meng, Weici Wang, Qianqian Ye, Lin Hu, Taoming Li & Tao Yin. (2019) A novel analytical method to assess the effect of imipenem/cilastatin on liver function laboratory indexes in Chinese underage inpatients: Probability distribution curve. PLOS ONE 14:10, pages e0224352.
Crossref
Crossref
Le Zou, Fanqi Meng, Lin Hu, Qi Huang, Min Liu & Tao Yin. (2019) A novel reversed-phase high-performance liquid chromatographic assay for the simultaneous determination of imipenem and meropenem in human plasma and its application in TDM. Journal of Pharmaceutical and Biomedical Analysis 169, pages 142-150.
Crossref
Crossref
Peter M Hawkey, Roderic E Warren, David M Livermore, Cliodna A M McNulty, David A Enoch, Jonathan A Otter & A Peter R Wilson. (2018) Treatment of infections caused by multidrug-resistant Gram-negative bacteria: report of the British Society for Antimicrobial Chemotherapy/Healthcare Infection Society/British Infection Association Joint Working Party†. Journal of Antimicrobial Chemotherapy 73:suppl_3, pages iii2-iii78.
Crossref
Crossref
A. Cherkaoui, S.M. Diene, A. Renzoni, S. Emonet, G. Renzi, P. François & J. Schrenzel. (2017) Imipenem heteroresistance in nontypeable Haemophilus influenzae is linked to a combination of altered PBP3, slow drug influx and direct efflux regulation. Clinical Microbiology and Infection 23:2, pages 118.e9-118.e19.
Crossref
Crossref
Soumen Choudhury, Kannan Kandasamy, Bhojane Somnath Maruti, M. Pule Addison, Jaya Kiran Kasa, Sazad A. Darzi, Thakur Uttam Singh, Subhashree Parida, Jeevan Ranjan Dash, Vishakha Singh & Santosh Kumar Mishra. (2015) Atorvastatin along with imipenem attenuates acute lung injury in sepsis through decrease in inflammatory mediators and bacterial load. European Journal of Pharmacology 765, pages 447-456.
Crossref
Crossref
Soumen Choudhury, Kandasamy Kannan, M. Pule Addison, Sazad A. Darzi, Vishakha Singh, Thakur Uttam Singh, Ramasamy Thangamalai, Jeevan Ranjan Dash, Subhashree Parida, Biplab Debroy, Avishek Paul & Santosh Kumar Mishra. (2015) Combined treatment with atorvastatin and imipenem improves survival and vascular functions in mouse model of sepsis. Vascular Pharmacology 71, pages 139-150.
Crossref
Crossref
O. Zusman, L. Farbman, Z. Tredler, V. Daitch, A. Lador, L. Leibovici & M. Paul. (2015) Association between hypoalbuminemia and mortality among subjects treated with ertapenem versus other carbapenems: prospective cohort study. Clinical Microbiology and Infection 21:1, pages 54-58.
Crossref
Crossref
Judyta Cielecka-Piontek, Magdalena Paczkowska, Kornelia Lewandowska, Boleslaw Barszcz, Przemyslaw Zalewski & Piotr Garbacki. (2013) Solid-state stability study of meropenem – solutions based on spectrophotometric analysis. Chemistry Central Journal 7:1.
Crossref
Crossref
Pragyan Swagatika Panda, Surya Kumar Dube, Suman Sarkar & Dinesh Kumar Singh. (2013) Metabolic alkalosis: A less appreciated side effect of Imipenem-cilastatin use. Indian Journal of Critical Care Medicine 17:4, pages 263-264.
Crossref
Crossref
Horng-Chyuan Lin, Shu-Min Lin, Chih-Teng Yu, Chien-Ying Liu, Kang-Yun Lee, Yu-Lun Lo, Ting-Yu Lin, Han-Pin Kuo, Chih-Hsi Kuo, Fu-Tsai Chung, Tsai-Yu Wang, Te-Chih Hsiung & Fu-Tsai Chung. (2011) Incidence and Outcome of Healthcare-Associated Acinetobacter baumannii in Chronically Ventilated Patients in a Tertiary Care Hospital in Taiwan. The American Journal of the Medical Sciences 341:5, pages 361-366.
Crossref
Crossref
J.N. Kattan, M.V. Villegas & J.P. Quinn. (2008) New developments in carbapenems. Clinical Microbiology and Infection 14:12, pages 1102-1111.
Crossref
Crossref
Lubos Drgona, Mical Paul, Giampaolo Bucaneve, Thierry Calandra & Francesco Menichetti. (2007) The need for aminoglycosides in combination with β-lactams for high-risk, febrile neutropaenic patients with leukaemia. European Journal of Cancer Supplements 5:2, pages 13-22.
Crossref
Crossref
George G Zhanel, Ryan Wiebe, Leanne Dilay, Kristjan Thomson, Ethan Rubinstein, Daryl J Hoban, Ayman M Noreddin & James A Karlowsky. (2007) Comparative Review of the Carbapenems. Drugs 67:7, pages 1027-1052.
Crossref
Crossref
Peter Linden. (2007) Safety Profile of Meropenem. Drug Safety 30:8, pages 657-668.
Crossref
Crossref
Steven J. Edwards, Helen E. Campbell & Jonathan M. Plumb. (2006) Cost-utility analysis comparing meropenem with imipenem plus cilastatin in the treatment of severe infections in intensive care. The European Journal of Health Economics 7:1, pages 72-78.
Crossref
Crossref